Clinical Trial Update: Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Brentuximab Vedotin as maintenance therapy after allogeneic hematopoietic stem cell transplant in cutaneous T-cell lymphoma. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin | Phase 3 | Status: NOT_YET_RECRUITING